ContextProstate cancer is the most common nonskin cancer and second most common
cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically
surgical or medical castration, is the first line of treatment against advanced prostate cancer
and is also used as an adjuvant to local treatment of high-risk disease. ObjectiveTo review
systematically the evidence on the risks and benefits of ADT for prostate cancer as well as
clinical management of its adverse effects. Evidence AcquisitionWe performed MEDLINE …